Page 27 - Read Online

Page 12 of 12 Lo et al. J Cancer Metastasis Treat 2022;8:30 https://dx.doi.org/10.20517/2394-4722.2022.48

discussion 782. DOI PubMed PMC
13. Versteijne E, van Dam JL, Suker M, et al. Neoadjuvant chemoradiotherapy versus upfront surgery for resectable and borderline
resectable pancreatic cancer: long-term results of the dutch randomized preopanc trial. J Clin Oncol 2022;40:1220-30. DOI PubMed
14. Jang JY, Han Y, Lee H, et al. Oncological benefits of neoadjuvant chemoradiation with gemcitabine versus upfront surgery in patients
with borderline resectable pancreatic cancer: a prospective, randomized, open-label, multicenter phase 2/3 trial. Ann Surg
2018;268:215-22. DOI PubMed
15. Murphy JE, Wo JY, Ryan DP, et al. Total neoadjuvant therapy with FOLFIRINOX followed by individualized chemoradiotherapy for
borderline resectable pancreatic adenocarcinoma: a phase 2 clinical trial. JAMA Oncol 2018;4:963-9. DOI PubMed PMC
16. Ghaneh P, Palmer DH, Cicconi S, et al. ESPAC-5F: four-arm, prospective, multicenter, international randomized phase II trial of
immediate surgery compared with neoadjuvant gemcitabine plus capecitabine (GEMCAP) or FOLFIRINOX or chemoradiotherapy
(CRT) in patients with borderline resectable pancreatic cancer. JCO 2020;38:4505-4505. DOI
17. Reni M, Zanon S, Balzano G, et al. A randomised phase 2 trial of nab-paclitaxel plus gemcitabine with or without capecitabine and
cisplatin in locally advanced or borderline resectable pancreatic adenocarcinoma. Eur J Cancer 2018;102:95-102. DOI PubMed
18. Hammel P, Huguet F, van Laethem JL, et al. Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally
advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib: the LAP07 randomized clinical trial.
JAMA 2016;315:1844-53. DOI PubMed
19. Murphy JE, Wo JY, Ryan DP, et al. Total neoadjuvant therapy with FOLFIRINOX in combination with losartan followed by
chemoradiotherapy for locally advanced pancreatic cancer: a phase 2 clinical trial. JAMA Oncol 2019;5:1020-7. DOI PubMed PMC
20. Philip PA, Lacy J, Portales F, et al. Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a
multicentre, open-label phase 2 study. Lancet Gastroenterol Hepatol 2020;5:285-94. DOI PubMed
21. Kunzmann V, Siveke JT, Algül H, et al. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by
FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised,
phase 2 trial. Lancet Gastroenterol Hepatol 2021;6:128-38. DOI PubMed
22. Pancreatic Adenocarcinoma NCCN Guidelines Version 1.2022. NCCN. Available from: https://www.nccn.org/guidelines/guidelines-
detail?category=1&id=1455 [Last accessed on 5 August 2022].
23. Vauthey JN, Dixon E. AHPBA/SSO/SSAT consensus conference on resectable and borderline resectable pancreatic cancer: rationale
and overview of the conference. Ann Surg Oncol 2009;16:1725-6. DOI PubMed
24. Varadhachary GR. Borderline resectable pancreatic cancer, Pancreatic Cancer. New York: Springer; 2018. pp. 1001-20. Available
from: http://www.scopus.com/inward/record.url?scp=85054047248&partnerID=8YFLogxK [Last accessed on 5 August 2022].
25. Katz MH, Marsh R, Herman JM, et al. Borderline resectable pancreatic cancer: need for standardization and methods for optimal
clinical trial design. Ann Surg Oncol 2013;20:2787-95. DOI PubMed PMC
26. Isaji S, Mizuno S, Windsor JA, et al. International consensus on definition and criteria of borderline resectable pancreatic ductal
adenocarcinoma 2017. Pancreatology 2018;18:2-11. DOI PubMed
27. Bockhorn M, Uzunoglu FG, Adham M, et al. Borderline resectable pancreatic cancer: a consensus statement by the International Study
Group of Pancreatic Surgery (ISGPS). Surgery 2014;155:977-88. DOI PubMed
28. Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med
2013;369:1691-703. DOI PubMed PMC
29. Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med
2011;364:1817-25. DOI PubMed
30. Janssen QP, Buettner S, Suker M, et al. Neoadjuvant FOLFIRINOX in patients with borderline resectable pancreatic cancer: a
systematic review and patient-level meta-analysis. J Natl Cancer Inst 2019;111:782-94. DOI PubMed PMC
31. Versteijne E, Suker M, Groothuis K, et al. Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline
resectable pancreatic cancer: results of the dutch randomized phase III PREOPANC trial. J Clin Oncol 2020;38:1763-73. DOI
PubMed PMC
32. Katz MHG, Ou FS, Herman JM, et al. Alliance for clinical trials in oncology (ALLIANCE) trial A021501: preoperative extended
chemotherapy vs. chemotherapy plus hypofractionated radiation therapy for borderline resectable adenocarcinoma of the head of the
pancreas. BMC Cancer 2017;17:505. DOI PubMed PMC
33. Katz MHG, Shi Q, Meyers JP, et al. Alliance A021501: preoperative mFOLFIRINOX or mFOLFIRINOX plus hypofractionated
radiation therapy (RT) for borderline resectable (BR) adenocarcinoma of the pancreas. JCO 2021;39:377-377. DOI
34. Institut de Cancérologie de Lorraine. Two arm, prospective, multicenter randomized phase II trial of neoadjuvant modified folfirinox
regimen, with or without preoperative concomitant chemoradiotherapy in patients with borderline resectable pancreatic carcinoma,
2022. Available from: https://clinicaltrials.gov/ct2/show/NCT02676349 [Last accessed on 5 August 2022].
35. Suker M, Beumer BR, Sadot E, et al. FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level
meta-analysis. Lancet Oncol 2016;17:801-10. DOI PubMed PMC
36. Wang S, Li Y, Xing C, et al. Tumor microenvironment in chemoresistance, metastasis and immunotherapy of pancreatic cancer. Am J
Cancer Res 2020;10:1937-53. PubMed PMC
37. Palta M, Godfrey D, Goodman KA, et al. Radiation therapy for pancreatic cancer: executive summary of an ASTRO clinical practice
guideline. Pract Radiat Oncol 2019;9:322-32. DOI PubMed